Beyond Air (NASDAQ:XAIR) Issues Quarterly Earnings Results

Beyond Air (NASDAQ:XAIR) announced its quarterly earnings results on Friday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.31), Zacks reports. Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%.The business had revenue of $2.19 million for the quarter, compared to analyst estimates of $2.15 million.

Here are the key takeaways from Beyond Air’s conference call:

• Revenue grew 105% year‑over‑year to $2.2M, with an installed base of more than 45 hospitals, customer retention above 90%, and over half of customers on multi‑year agreements, indicating early commercial traction.
• Commercial momentum includes national GPO agreements with Premier and Vizient, the first sale into a VA Medical Center, expansion of distribution to 40 countries, and repeat international accessory orders, supporting broader adoption.
• Management expects FDA clearance for the Gen 2 LungFit PH system by the end of calendar 2026 and says Gen 2’s smaller size, transport compatibility, simplified operation, and extended service intervals should expand the addressable market.
• Timing risk remains for Gen 2 because launch is contingent on a contract manufacturer inspection and continued engagement with the FDA, which could delay approval or commercialization.
• Operating expenses fell ~36% YoY to about $6.9M, net loss narrowed to $7.3M, cash and equivalents were $17.8M at quarter end, and subsequent financings give management confidence in a runway into calendar 2027, albeit conditional on meeting revenue and cost targets.

Beyond Air Stock Performance

Shares of XAIR opened at $1.05 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.24 and a quick ratio of 3.73. The firm’s 50 day moving average is $1.14 and its 200-day moving average is $1.81. Beyond Air has a 12-month low of $0.67 and a 12-month high of $8.01. The stock has a market capitalization of $8.41 million, a P/E ratio of -0.19 and a beta of 0.39.

Analyst Ratings Changes

Several equities research analysts recently weighed in on XAIR shares. Rodman & Renshaw initiated coverage on shares of Beyond Air in a report on Tuesday, January 20th. They issued a “buy” rating for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Beyond Air in a research note on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of Beyond Air in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Beyond Air has a consensus rating of “Hold” and an average target price of $11.00.

Institutional Investors Weigh In On Beyond Air

A number of institutional investors and hedge funds have recently modified their holdings of XAIR. Geode Capital Management LLC grew its holdings in shares of Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after acquiring an additional 24,695 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Beyond Air in the 3rd quarter valued at $1,753,000. Virtu Financial LLC purchased a new position in Beyond Air in the 3rd quarter worth about $48,000. Finally, Osaic Holdings Inc. raised its holdings in Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after buying an additional 34,000 shares during the period. Institutional investors and hedge funds own 31.50% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.